For: | Singh AK, Durairajan SSK, Iyaswamy A, Williams LL. Elucidating the role of gut microbiota dysbiosis in hyperuricemia and gout: Insights and therapeutic strategies. World J Gastroenterol 2024; 30(40): 4404-4410 [PMID: 39494101 DOI: 10.3748/wjg.v30.i40.4404] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v30/i40/4404.htm |
Number | Citing Articles |
1 |
Supriti Patnaik, Siva Sundara Kumar Durairajan, Abhay Kumar Singh, Senthilkumar Krishnamoorthi, Ashok Iyaswamy, Shiva Prasad Mandavi, Rajesh Jeewon, Leonard L Williams. Role of <i>Candida</i> species in pathogenesis, immune regulation, and prognostic tools for managing ulcerative colitis and Crohn's disease. World Journal of Gastroenterology 2024; 30(48): 5212-5220 doi: 10.3748/wjg.v30.i48.5212
|
2 |
Jia-Wei Tang, Alfred Chin Yen Tay, Liang Wang. Interpretive prediction of hyperuricemia and gout patients via machine learning analysis of human gut microbiome. BMC Microbiology 2025; 25(1) doi: 10.1186/s12866-025-04125-x
|
3 |
Ying Yang, Yu Wang, Jinjian Huang, Yi Xu, Xiaoyang Yin, Zhijian Lin, Bing Zhang. Influence of Gut Microbiota-Derived Butyrate on Intestinal Uric Acid Excretion and Hyperuricemia Regulation by Cichorium intybus L.. International Journal of Molecular Sciences 2025; 26(13): 6413 doi: 10.3390/ijms26136413
|
4 |
Tingli Qu, Nan Zhang, Junjie Cai, Chen Li, Yue Zhang, Xinxue Xu, Shuai Zhang, Wangwei Lv, Taigang Liang. Integrated bioinformatics and multi-omics reveal Astragalus extract’s gut-kidney axis mechanism in hyperuricemic nephropathy via purine metabolism. Phytomedicine 2025; 146: 157121 doi: 10.1016/j.phymed.2025.157121
|
5 |
Xiaoxue Hou, Mengmeng Wang, Tongyuan Hu, Zhinan Wu, Hewei Liang, Yiyi Zhong, Zhihui Ma, Haifeng Zhang, Liang Xiao, Wenjin Zhang, Yuanqiang Zou. Evaluation of the safety and probiotic properties of Limosilactobacillus fermentum BGI-AF16, a uric acid-lowering probiotic strain. Microbial Pathogenesis 2025; 201: 107382 doi: 10.1016/j.micpath.2025.107382
|
6 |
Xinru Huang, Hao Wu, Xiao Wu, Weiwei Su, Peibo Li. Naringenin/naringin therapeutic effects and the role of intestinal microflora in them. Pharmacological Research 2025; 219: 107871 doi: 10.1016/j.phrs.2025.107871
|
7 |
Orsolya I. Gaal, Leo A.B. Joosten, Tania O. Crișan. Targeting innate immune memory: a new paradigm for gout treatment. Exploration of Musculoskeletal Diseases 2025; 3 doi: 10.37349/emd.2025.1007103
|
8 |
Wei-Ting Tseng, Xiang-Ru Kong, Yu-Tsung Han, Wen-Yang Lin, Deyi Yin, Lei Du, Jingli Xie, Tien-Hung Chang. Lacticaseibacillus paracasei LT12—A Probiotic Strain That Reduces Hyperuricemia via Inhibiting XO Activity and Regulating Renal Uric Acid Transportation Protein. Fermentation 2025; 11(2): 96 doi: 10.3390/fermentation11020096
|
9 |
Yujing Cui, Haoyue Guan, Samuel Kumi Okyere, Zixuan Hua, Youtian Deng, Huidan Deng, Zhihua Ren, Junliang Deng. Microbial Guardians or Foes? Metagenomics Reveal Association of Gut Microbiota in Intestinal Toxicity Caused by DON in Mice. International Journal of Molecular Sciences 2025; 26(4): 1712 doi: 10.3390/ijms26041712
|
10 |
Wujin Chen, Tingting Tian, Jingru Zhou, Dan Yang, Meiting Liang, Yi He, Shanshan Yang, Dilinuer Aikepa, Yuping Sun. Safety Evaluation of Human-Derived Uric Acid Degrading Lacticaseibacillus paracasei M2a and Its Impact on Gut Microbiota. Probiotics and Antimicrobial Proteins 2025; doi: 10.1007/s12602-025-10562-x
|
11 |
Yueying Cui, Peiyu An, Feng Li, Fengsen Duan, Zusong Mei, Qiao Ye, Guangyun Wang, Haitao Zhang, Yuan Luo. Strategies to reduce uric acid through gut microbiota intervention. Frontiers in Microbiology 2025; 16 doi: 10.3389/fmicb.2025.1654152
|